

BioRestorative Therapies, Inc.
Form 8-K
March 28, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report: March 24, 2014
(Date of earliest event reported)

BIORESTORATIVE THERAPIES, INC.
(Exact Name of Registrant as Specified in Charter)

| | | |
|--|--------------------------|---|
| Nevada | 000-54402 | 91-1835664 |
| (State or Other Jurisdiction of Incorporation) | (Commission File No.) | (I R S E m p l o y e r Identification Number) |

555 Heritage Drive, 33458
Jupiter, Florida
(Address of Principal
Executive Offices) (Zip
Code)

Registrant's telephone number, including area code: (561) 904-6070

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement.

On March 24, 2014, BioRestorative Therapies, Inc. (the “Company”) entered into a Research Agreement (the “Agreement”) with Pfizer Inc.

Pursuant to the Agreement, the Company has been engaged to provide research and development services with regard to brown fat. The Agreement provides for an initial payment to the Company of \$250,000 and the payment of up to an additional \$525,000 during the two year term of the Agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIORESTORATIVE THERAPIES,
INC.

Dated: March 28, 2014

By:

/s/ Mark Weinreb
Mark Weinreb
Chief Executive Officer